Andrew Wachtel, MD
Pulmonary Disease · Los Angeles, CANPI 1922108778
Payments from drug & device makers
Across 593 payments — averaging $9888.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3.5M
- Teva Pharmaceuticals USA, Inc.$461K
- Chiesi USA, Inc.$447K
- Amphastar Pharmaceuticals, Inc.$413K
- GSK$324K
- Hikma Pharmaceuticals USA$304K
- plus $403K from 23 others
Across 1 payment — averaging $242.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$242
What the payments were for
- Consulting fees$2,30013%
- Speaking & faculty fees$8,19645%
- Travel & lodging$3,00717%
- Food & beverage$4,54125%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $3,511,962 |
| Teva Pharmaceuticals USA, Inc. | 72 | $461,377 |
| Chiesi USA, Inc. | 150 | $446,641 |
| Amphastar Pharmaceuticals, Inc. | 3 | $412,975 |
| GSK | 95 | $324,375 |
| Hikma Pharmaceuticals USA | 11 | $303,744 |
| Sanofi US Services Inc. | 36 | $176,317 |
| Novartis | 17 | $158,932 |
| Shionogi Inc | 20 | $53,014 |
| Regeneron Healthcare Solutions, Inc. | 25 | $7,163 |
| Genentech USA, Inc. | 12 | $3,281 |
| Sanofi | 4 | $2,493 |
| Boehringer Ingelheim | 12 | $264 |
| Insmed, Inc. | 12 | $259 |
| Electromed, Inc. | 8 | $175 |
| Advanced Respiratory, Inc | 7 | $172 |
| Grifols USA, LLC | 5 | $135 |
| Nabriva Therapeutics, PLC | 5 | $103 |
| AbbVie(2 entities) | 4 | $77 |
| Mallinckrodt Enterprises LLC | 2 | $59 |
| Philips North America LLC | 2 | $51 |
| Amgen | 2 | $47 |
| Mylan Specialty L.p. | 2 | $46 |
| Circassia Inc. | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $31 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Pulmonx Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,863,800 in reported general payments places this provider in the 95th percentile of 1,261 pulmonary disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 288 | $265,026 |
| OpsumitMacitentan | 12 | $138,838 |
| Dupixent PenDupilumab | 35 | $135,016 |
| Dupixent SyringeDupilumab | 24 | $104,823 |
| Breo ElliptaFluticasone/Vilanterol | 159 | $88,221 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 117 | $73,552 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $41,910 |
| Spiriva RespimatTiotropium Bromide | 33 | $32,668 |
| SymbicortBudesonide/Formoterol Fumarate | 80 | $26,756 |
| XareltoRivaroxaban | 34 | $24,166 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 35 | $21,760 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $20,649 |
| DuleraMometasone/Formoterol | 40 | $19,922 |
| BreynaBudesonide/Formoterol Fumarate | 66 | $17,392 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 100 | $14,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $324,375 | $426,800564 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $21 | $138,83812 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere, Pulmicort Flexhaler | $3,511,962 | $96,668172 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Pradaxa | $264 | $55,46173 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $461,377 | $5,16918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Los Angeles
- Toby MaherLos Angeles$27.6M
- Michael RothLos Angeles$4.5M
- Rajan SaggarLos Angeles$3.3M
- Stephen Samuel WeigtLos Angeles$2.1M
- Robert WolfeLos Angeles$1.9M
- Igor BarjaktarevicLos Angeles$1.9M
- Shelley ShapiroLos Angeles$1M
- Victor TapsonLos Angeles$931K
- John BelperioLos Angeles$905K
- Sivagini GaneshLos Angeles$816K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.